Immunovant Inc

argenx SE

batoclimab — chronic inflammatory demyelinating polyneuropathy

Dilution score: 26/100 (MEDIUM), 24.0 months cash

Short interest: 25.83% of float, squeeze risk: HIGH

151 PubMed publications found for Immunovant

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

IL-11 receptor is a novel target for drug development with pharmacological activity in fibro-inflammatory disease.

Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.

Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20.

Therapeutic Approaches for Cutaneous Lupus Erythematosus: a Changing Landscape of Clinical Trials.

Dilution score: 22/100 (LOW), 46.2 months cash

Short interest: 25.84% of float, squeeze risk: HIGH

Short interest: 23.59% of float, squeeze risk: HIGH

Short interest: 23.92% of float, squeeze risk: HIGH

Short interest: 24.08% of float, squeeze risk: HIGH

Dilution score: 25/100 (LOW), 24.0 months cash

Short interest: 24.13% of float, squeeze risk: HIGH

Dilution score: 22/100 (LOW), 45.8 months cash

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

150 PubMed publications found for Immunovant

Minimal Symptom Expression in Generalized Myasthenia Gravis: A Valuable Patient-Centric Treatment Goal.

149 PubMed publications found for Immunovant

Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis.

Short interest: 25.31% of float, squeeze risk: HIGH

147 PubMed publications found for Immunovant

Cluster headache and comorbidities, income and education: A nationwide registry-based matched cohort study.

SW convergence: 50/100 (Neutral), 2 bullish / 1 bearish signals

Short interest: 25.28% of float, squeeze risk: HIGH

Short interest: 25.27% of float, squeeze risk: HIGH

Short interest: 25.26% of float, squeeze risk: HIGH

145 PubMed publications found for Immunovant

Nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies: results from the phase 2a DAISY-RA study.

Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD.

<article class="bts-verified-summary" data-ticker="IMVT">
<p>Immunovant Inc (IMVT) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>IMVT has 16 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0001764013 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22IMVT%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR — 0001764013

Immunovant Inc (IMVT) — BioTechSigns Verified Summary

Immunovant Inc (IMVT) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

IMVT has 16 Form 4 insider filings recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0001764013. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22IMVT%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11